Effects of antibiotic dry-cow therapy and internal teat sealant on milk somatic cell counts and clinical and subclinical mastitis in early lactation.
The objective of this study was to determine the efficacy of an internal teat sealant (TS; Teatseal; Zoetis Australia, Silverwater, NSW, Australia), when used in combination with antibiotic dry-cow therapy (ADCT) administered at dry-off, on milk individual somatic cell count (ISCC), milk production and components, and the incidence of clinical and subclinical mastitis in dairy cows up to 60 d after calving, when compared with ADCT only. Multiparous Holstein, Jersey, or Holstein cross cows (n=2,200) from 8 farms in southern and eastern Australia were randomly assigned to treatment of all 4 quarters with ADCT alone or with ADCT plus TS (ADCT + TS) at dry-off in this randomized, multisite clinical trial. Individual milk yield, fat and protein percentages, and ISCC were measured at intervals of 14±3 d after calving for the first 60 d of lactation. The first measurement occurred between 10 and 24 d after calving. Clinical mastitis and health events were recorded from dry-off to 60 d of lactation. Milk samples were collected from first cases of clinical mastitis and subjected to bacteriology. Treatment and the interaction of treatment by time did not affect milk yield, ISCC weighted by milk yield, or fat and protein percentages. Treatment with ADCT + TS decreased geometric mean ISCC compared with treatment with ADCT alone over the first 60 d of lactation. Geometric mean ISCC (×10(3) cells/mL) was 32.0 [95% confidence interval (CI): 26.8 to 38.3] and 43.5 (95% CI: 36.2 to 52.1) for ADCT + TS and ADCT alone, respectively. The odds of at least 1 case of subclinical mastitis (ISCC ≥250,000 cells/mL) were 1.9 times higher (95% CI: 1.4 to 2.6) with ADCT alone in the first 60 d of lactation compared with ADCT + TS. Use of ADCT + TS reduced the estimated incidence of at least 1 case of subclinical mastitis on all 8 farms, compared with use of ADCT alone. Only 4 cows that calved 40 to 100 d after dry-off had a first case of clinical mastitis in the dry period. Five percent of cows (76 cases from 1,528 cows included in this analysis) that calved 40 to 100 d after dry-off had a first case of clinical mastitis between 0 and 60 d in milk. Of these first cases of clinical mastitis, 43 cases (5.7% of 761 cows) occurred in the ADCT group and 33 (4.3% of 767 cows) in the ADCT + TS group, but this was not significantly different. Proportional hazards estimates of survival showed no difference in the number of days postcalving to detection of first cases of clinical mastitis between the ADCT and ADCT + TS groups over the first 60 d postpartum. The estimated hazard ratio for clinical mastitis over this period in the ADCT + TS cows (relative to ADCT alone) was 0.70 (95% CI: 0.43 to 1.14). The combination of ADCT and TS provides benefits over ADCT use alone through improved prevention of subclinical mastitis and reduced ISCC in the first 60 d of lactation.
Scibus, Camden, New South Wales, Australia, 2570. Electronic address: heleng@scibus.com.au.
H M
HM
Golder
Zoetis Australia Research and Manufacturing Pty. Ltd., Parkville, Victoria, Australia, 3052.
A
A
Hodge
Scibus, Camden, New South Wales, Australia, 2570.
I J
IJ
Lean
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001315:Australia; D001729:Bismuth / Q000008:administration & dosage; D002417:Cattle; D002452:Cell Count / Q000662:veterinary; D005260:Female; D007774:Lactation; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000382:microbiology*; D008414:Mastitis, Bovine / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control*; D008892:Milk / Q000166:cytology* / Q000382:microbiology; D010232:Paraffin / Q000008:administration & dosage; D016016:Proportional Hazards Models
D000900:Anti-Bacterial Agents; D010232:Paraffin; C010804:bismuth subnitrate; D001729:Bismuth
dry-cow therapy; individual somatic cell count; intramammary infection; mastitis; teat sealant